A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations Meeting Abstract
| Authors: | Aftimos, P. G.; Oliveira, M.; Punie, K.; Boni, V.; Hamilton, E. P.; Gucalp, A.; Shah, P. D.; de Miguel, M. J.; Sharma, P.; Bauman, L.; Campeau, E.; Attwell, S.; Snyder, M.; Norek, K.; Johnson, E.; Silverman, M. H.; Lakhotia, S.; Domchek, S. M.; Litton, J. K.; Robson, M. E. |
| Abstract Title: | A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300081 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.1023 |
| Notes: | Meeting Abstract: 1023 -- This meeting was also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work